MA50468A - Posologie à intervalle étendu de natalizumab - Google Patents

Posologie à intervalle étendu de natalizumab

Info

Publication number
MA50468A
MA50468A MA050468A MA50468A MA50468A MA 50468 A MA50468 A MA 50468A MA 050468 A MA050468 A MA 050468A MA 50468 A MA50468 A MA 50468A MA 50468 A MA50468 A MA 50468A
Authority
MA
Morocco
Prior art keywords
natalizumab
long
term dosage
dosage
term
Prior art date
Application number
MA050468A
Other languages
English (en)
Inventor
Nolan Robert Campbell
Ih Chang
Bharath Kumar Kandadi Muralidharan
Ivan Alexandrov Nestorov
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA50468A publication Critical patent/MA50468A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA050468A 2017-10-26 2018-10-25 Posologie à intervalle étendu de natalizumab MA50468A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762577671P 2017-10-26 2017-10-26
US201762608048P 2017-12-20 2017-12-20
US201862717543P 2018-08-10 2018-08-10
US201862750184P 2018-10-24 2018-10-24

Publications (1)

Publication Number Publication Date
MA50468A true MA50468A (fr) 2021-04-21

Family

ID=64427197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050468A MA50468A (fr) 2017-10-26 2018-10-25 Posologie à intervalle étendu de natalizumab

Country Status (11)

Country Link
US (1) US20210188982A1 (fr)
EP (1) EP3700931A1 (fr)
JP (2) JP2021501152A (fr)
KR (1) KR20200088350A (fr)
CN (1) CN111683967A (fr)
AU (1) AU2018355447A1 (fr)
CA (1) CA3080239A1 (fr)
IL (1) IL274163B1 (fr)
MA (1) MA50468A (fr)
MX (1) MX2020004238A (fr)
WO (1) WO2019084335A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243932A1 (fr) * 2020-11-14 2023-09-20 Biogen MA Inc. Schémas posologiques sous-cutanés biphasiques pour des anticorps anti-vla-4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098197B2 (en) 2011-06-03 2018-10-09 Cree, Inc. Lighting devices with individually compensating multi-color clusters
HUE043339T2 (hu) 2011-05-31 2019-08-28 Biogen Ma Inc Módszer a PML kockázatának megállapítására
WO2014193804A1 (fr) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp
WO2018068104A1 (fr) * 2016-10-14 2018-04-19 StickyCell Pty Ltd Dosages de la fonction d'adhésion leucocytaire, dispositifs et/ou utilisations

Also Published As

Publication number Publication date
US20210188982A1 (en) 2021-06-24
EP3700931A1 (fr) 2020-09-02
WO2019084335A1 (fr) 2019-05-02
MX2020004238A (es) 2020-10-05
CN111683967A (zh) 2020-09-18
JP2023164611A (ja) 2023-11-10
AU2018355447A1 (en) 2020-05-21
CA3080239A1 (fr) 2019-05-02
IL274163B1 (en) 2024-07-01
KR20200088350A (ko) 2020-07-22
JP2021501152A (ja) 2021-01-14
IL274163A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
UA37664S (uk) Елемент взуття
DK3485237T3 (da) Dosismålesystemer
DOS2018000077S (es) Inhalador
DK3600005T3 (da) Multimodalitetsanalyse af kropssammensætning
MA44702A (fr) Compositions de suspension à libération prolongée
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
UA37665S (uk) Верхній елемент взуття
DK3583943T3 (da) Farmaceutisk sammensætning
UA38569S (uk) Інгалятор
ES2981585T3 (es) Inhaladores
DK3645090T3 (da) Inhalator
BR112018000296A2 (pt) ensaios de potência de influenza
DK3672941T3 (da) Pyridylpyridonforbindelser
ES2774344T8 (es) Compensación de deriva
IT201700041695A1 (it) Apparato di misura bio-impedenziometrica di un paziente
MA50468A (fr) Posologie à intervalle étendu de natalizumab
DK3728220T3 (da) Farmaceutiske forbindelser
DK3704328T3 (da) Flydende gulv
DK3672962T3 (da) Morpholinylpyridonforbindelser
ES2747993T8 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam
IT201700068126A1 (it) Struttura di filtropressa
IT201700010606A1 (it) GenialCombi di Moscarelli
MA49557A (fr) Formulations à action prolongée
UA36698S (uk) Набір форм для випікання